StockData
Ascendis Pharma A/S logo

Ascendis Pharma A/S (ASND) stock

ASNDNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Score 7/30
$270.33−0.86 (-0.32%)

Close on Nov 18, 2026Market cap $16.75BP/E 22.2Yield –

Ascendis Pharma A/S net income

Net income is the profit left for shareholders after every expense, interest and tax.

Ascendis Pharma A/S's net income for the twelve months ending Jun 30, 2026 was €741.76M. For fiscal 2025 it was -€228.03M. The highest annual figure on record is -€130.10M in fiscal 2018.

Annual net income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-€228.03M–
FY2024Dec 31, 2024-€378.08M–
FY2023Dec 31, 2023-€481.45M–
FY2022Dec 31, 2022-€583.19M–
FY2021Dec 31, 2021-€383.58M–
FY2020Dec 31, 2020-€418.96M–
FY2019Dec 31, 2019-€218.02M–
FY2018Dec 31, 2018-€130.10M–

Quarterly net income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026€206.97M–
Q1 FY2026Mar 31, 2026€629.34M–
Q4 FY2025Dec 31, 2025-€33.56M–
Q3 FY2025Sep 30, 2025-€60.99M–
Q2 FY2025Jun 30, 2025-€38.86M–
Q1 FY2025Mar 31, 2025-€94.63M–
Q4 FY2024Dec 31, 2024-€38.47M–
Q3 FY2024Sep 30, 2024-€99.20M–
Q2 FY2024Jun 30, 2024-€109.38M–
Q1 FY2024Mar 31, 2024-€131.04M–
Q4 FY2023Dec 31, 2023-€86.88M–
Q3 FY2023Sep 30, 2023-€162.22M–
Q2 FY2023Jun 30, 2023-€121.43M–
Q1 FY2023Mar 31, 2023-€110.91M–
Q4 FY2022Dec 31, 2022-€207.42M–
Q3 FY2022Sep 30, 2022-€168.96M–
Q2 FY2022Jun 30, 2022-€81.32M–
Q1 FY2022Mar 31, 2022-€125.50M–
Q4 FY2021Dec 31, 2021-€106.06M–
Q3 FY2021Sep 30, 2021-€80.35M–
Q2 FY2021Jun 30, 2021-€134.37M–
Q1 FY2021Mar 31, 2021-€62.79M–
Q4 FY2020Dec 31, 2020-€138.97M–
Q3 FY2020Sep 30, 2020-€121.74M–
Q2 FY2020Jun 30, 2020-€94.93M–
Q1 FY2020Mar 31, 2020-€63.32M–
Q4 FY2019Dec 31, 2019-€80.36M–
Q3 FY2019Sep 30, 2019-€25.11M–
Q2 FY2019Jun 30, 2019-€58.90M–

More Ascendis Pharma A/S figures

See a number that looks wrong?